Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: Why pneumonectomy should be avoided

Lung Cancer

Volumn 68, Issue 2, 2010, Pages 222-227

  Kappers, Ingrid ^a   van Sandick, Johanna W ^a   Burgers, Sjaak A ^a   Belderbos, José S A ^a   van Zandwijk, Nico ^a   Klomp, Houke M ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Antineoplastic agents; Neoadjuvant therapy; Non small cell lung carcinoma; Pneumonectomy; Radiotherapy; Surgery

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURGICAL MORTALITY; THORACOTOMY; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PNEUMONECTOMY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 77950459368     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.07.001     Document Type: Article

References (27)

1. Martini N., Flehinger B.J. The role of surgery in N2 lung cancer. Surg Clin North Am 1987, 67(5):1037-1049.
2. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 1997, 111(6):1710-1717.
3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995 7;311(7010):899-909.
4. Albain K.S. Induction therapy followed by definitive local control for stage III non-small-cell lung cancer. A review, with a focus on recent trimodality trials. Chest 1993, 103(1 SUPP1):43S-50S.
5. Strauss G.M., Langer M.P., Elias A.D., Skarin A.T., Sugarbaker D.J. Multimodality treatment of stage IIIA non-small-cell lung carcinoma: a critical review of the literature and strategies for future research. J Clin Oncol 1992, 10(5):829-838.
6. van Meerbeeck J.P., Kramer G.W., Van Schil P.E., Legrand C., Smit E.F., Schramel F., et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007 Mar 21, 99(6):442-450.
7. Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith CJ, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup trial 0139 (RTOG 9309). J Clin Oncol [23]. 2005. Ref Type: Abstract.
8. Birim O., Maat A.P., Kappetein A.P., van Meerbeeck J.P., Damhuis R.A., Bogers A.J. Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer. Eur J Cardiothorac Surg 2003, 23(1):30-34.
9. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
10. Belderbos J., Uitterhoeve L., van Zandwijk N., Belderbos H., Rodrigus P., van de Vaart P., et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007, 43(1):114-121.
11. Van Zandwijk N., Smit E.F., Kramer G.W., Schramel F., Gans S., Festen J., et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000, 18(14):2658-2664.
12. EORTC 2008. http://www.eortc.be/protoc/details.asp?protocol=08013.
13. Yang C.H., Tsai C.M., Wang L.S., Lee Y.C., Chang C.J., Lui L.T., et al. Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer. Br J Cancer 2002 Jan 21, 86(2):190-195.
14. Cardenal F., Lopez-Cabrerizo M.P., Anton A., Alberola V., Massuti B., Carrato A., et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999, 17(1):12-18.
15. Crino L., Scagliotti G.V., Ricci S., De Marinis F., Rinaldi M., Gridelli C., et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999, 17(11):3522-3530.
16. Sandler A.B., Nemunaitis J., Denham C., von Pawel J., Cormier Y., Gatzemeier U., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000, 18(1):122-130.
17. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
18. Sculier J.P., Chansky K., Crowley J.J., Van Meerbeeck J., Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 2008, 3(5):457-466.
19. Robinson L.A., Ruckdeschel J.C., Wagner H., Stevens C.W. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines. 2nd edition. Chest 2007, 132(3 SUPP1):243S-265S.
20. Van Schil P., Van Meerbeeck J., Kramer G., Splinter T., Legrand C., Giaccone G., et al. Morbidity and mortality in the surgery arm of EORTC 08941 trial. Eur Respir J 2005, 26(2):192-197.
21. Venuta F., Anile M., Diso D., Ibrahim M., De G.T., Rolla M., et al. Operative complications and early mortality after induction therapy for lung cancer. Eur J Cardiothorac Surg 2007, 31(4):714-717.
22. Martin J., Ginsberg R.J., Abolhoda A., Bains M.S., Downey R.J., Korst R.J., et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 2001, 72(4):1149-1154.
23. Zhou X., Wang J., Wang J., Pan Y., Li J., Wang W., et al. Analysis of prognostic factors for surgery after neo-adjuvant therapy for stage III non-small cell lung cancer. J Huazhong Univ Sci Technol Med Sci 2008, 28(6):677-680.
24. Duque J.L., Ramos G., Castrodeza J., Cerezal J., Castanedo M., Yuste M.G., et al. Early complications in surgical treatment of lung cancer: a prospective, multicenter study. Grupo Cooperativo de Carcinoma Broncogenico de la Sociedad Espanola de Neumologia y Cirugia Toracica. Ann Thorac Surg 1997, 63(4):944-950.
25. Ginsberg R.J., Hill L.D., Eagan R.T., Thomas P., Mountain C.F., Deslauriers J., et al. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg 1983, 86(5):654-658.
26. Myrdal G., Gustafsson G., Lambe M., Horte L.G., Stahle E. Outcome after lung cancer surgery. Factors predicting early mortality and major morbidity. Eur J Cardiothorac Surg 2001, 20(4):694-699.
27. Wada H., Nakamura T., Nakamoto K., Maeda M., Watanabe Y. Thirty-day operative mortality for thoracotomy in lung cancer. J Thorac Cardiovasc Surg 1998, 115(1):70-73.